47 related articles for article (PubMed ID: 8543998)
1. Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy.
Denis-Bacelar AM; Chittenden SJ; McCready VR; Divoli A; Dearnaley DP; O'Sullivan JM; Johnson B; Flux GD
Br J Radiol; 2018 Apr; 91(1084):20170795. PubMed ID: 29293372
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II trials of
Denis-Bacelar AM; Chittenden SJ; Dearnaley DP; Divoli A; O'Sullivan JM; McCready VR; Johnson B; Du Y; Flux GD
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):620-629. PubMed ID: 27770145
[TBL] [Abstract][Full Text] [Related]
3. Tumor Burden and Intraosseous Metabolic Activity as Predictors of Bone Marrow Failure during Radioisotope Therapy in Metastasized Prostate Cancer Patients.
Fiz F; Sahbai S; Campi C; Weissinger M; Dittmann H; Marini C; Piana M; Sambuceti G; la Fougère C
Biomed Res Int; 2017; 2017():3905216. PubMed ID: 29435457
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of
Ranjbar H; Bagheri R; Miremad SM
Appl Radiat Isot; 2024 Jun; 208():111300. PubMed ID: 38531242
[TBL] [Abstract][Full Text] [Related]
5. A radiobiological model of metastatic burden reduction for molecular radiotherapy: application to patients with bone metastases.
Denis-Bacelar AM; Chittenden SJ; Murray I; Divoli A; Ralph McCready V; Dearnaley DP; O'Sullivan JM; Johnson B; Flux GD
Phys Med Biol; 2017 Apr; 62(7):2859-2870. PubMed ID: 28291739
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial).
van Dodewaard-de Jong JM; de Klerk JM; Bloemendal HJ; van Bezooijen BP; de Haas MJ; Wilson RH; O'Sullivan JM
Eur J Nucl Med Mol Imaging; 2011 Nov; 38(11):1990-8. PubMed ID: 21792569
[TBL] [Abstract][Full Text] [Related]
7. Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts.
Walrand S; Barone R; Pauwels S; Jamar F
Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1270-80. PubMed ID: 21318451
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of competitive inhibitors of protein binding for improving the pharmacokinetics of 186Re-MAG3-conjugated bisphosphonate (186Re-MAG3-HBP), an agent for treatment of painful bone metastases.
Ogawa K; Mukai T; Kawai K; Takamura N; Hanaoka H; Hashimoto K; Shiba K; Mori H; Saji H
Eur J Nucl Med Mol Imaging; 2009 Jan; 36(1):115-21. PubMed ID: 18709369
[TBL] [Abstract][Full Text] [Related]
9. 186Re-HEDP for metastatic bone pain in breast cancer patients.
Lam MG; de Klerk JM; van Rijk PP
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S162-70. PubMed ID: 15118846
[TBL] [Abstract][Full Text] [Related]
10. Re-HEDP : pharmacokinetic characterization, clinical and dosimetric evaluation in osseous metastatic patients with two levels of radiopharmaceutical dose.
Savio E; Gaudiano J; Robles AM; Balter H; Paolino A; López A; Hermida JC; De Marco E; Martinez G; Osinaga E; Knapp FF
BMC Nucl Med; 2001; 1(1):2. PubMed ID: 11734069
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations.
de Klerk JM; van het Schip AD; Zonnenberg BA; van Dijk A; Stokkel MP; Han SH; Blijham GH; van Rijk PP
J Nucl Med; 1994 Sep; 35(9):1423-8. PubMed ID: 8071686
[TBL] [Abstract][Full Text] [Related]
12. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
Liepe K; Hliscs R; Kropp J; Runge R; Knapp FF; Franke WG
J Nucl Med; 2003 Jun; 44(6):953-60. PubMed ID: 12791825
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer.
de Klerk JM; van het Schip AD; Zonnenberg BA; van Dijk A; Quirijnen JM; Blijham GH; van Rijk PP
J Nucl Med; 1996 Feb; 37(2):244-9. PubMed ID: 8667053
[TBL] [Abstract][Full Text] [Related]
14. Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP.
De Klerk JM; Zonnenberg BA; Blijham GH; Van Het Schip AD; Hoekstra A; Han SH; Quirijnen JM; Van Dijk A; Van Rijk PP
Anticancer Res; 1997; 17(3B):1773-7. PubMed ID: 9179233
[TBL] [Abstract][Full Text] [Related]
15. 186Re-etidronate. Efficacy of palliative radionuclide therapy for painful bone metastases.
Han SH; De Klerk JM; Zonnenberg BA; Tan S; Van Rijk PP
Q J Nucl Med; 2001 Mar; 45(1):84-90. PubMed ID: 11456380
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts.
de Klerk JM; van Dieren EB; van het Schip AD; Hoekstra A; Zonnenberg BA; van Dijk A; Rutgers DH; Blijham GH; van Rijk PP
J Nucl Med; 1996 Jan; 37(1):38-41. PubMed ID: 8543998
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
